Bourgeon Capital Management LLC Spero Therapeutics, Inc. Transaction History

Bourgeon Capital Management LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Jul 20, 2023	SELL	$1.42 - $1.95 $14,910 - $20,475	-10,500 Reduced 41.02%	15,100 $21,000
Q1 2023 Apr 17, 2023	BUY	$1.35 - $2.0 $16,875 - $25,000	12,500 Added 95.42%	25,600 $37,000
Q4 2022 Jan 20, 2023	SELL	$1.55 - $2.12 $11,625 - $15,900	-7,500 Reduced 36.41%	13,100 $0
Q3 2022 Oct 27, 2022	BUY	$0.68 - $2.2 $2,040 - $6,600	3,000 Added 17.05%	20,600 $41,000
Q2 2022 Jul 27, 2022	SELL	$0.74 - $7.44 $33,667 - $338,490	-45,496 Reduced 72.11%	17,600 $13,000
Q1 2022 May 03, 2022	BUY	$7.87 - $15.15 $93,259 - $179,527	11,850 Added 23.12%	63,096 $549,000
Q4 2021 Jan 31, 2022	BUY	$13.09 - $18.77 $124,355 - $178,315	9,500 Added 22.76%	51,246 $820,000
Q3 2021 Nov 09, 2021	BUY	$13.03 - $19.51 $543,950 - $814,464	41,746 New	41,746 $769,000
Q1 2021 May 13, 2021	SELL	$13.23 - $21.48 $202,961 - $329,524	-15,341 Closed	0 $0
Q4 2020 Jan 29, 2021	BUY	$11.65 - $22.07 $178,722 - $338,575	15,341 New	15,341 $297,000

13.9M

200

200

Ticker SPRO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 35,067,500
Market Cap $33.3M
Description
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to ...

Get notified when there are updates to the investment portfolio of Bourgeon Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Bourgeon Capital Management LLC with notifications on news.